BR112021005914A2 - derivados de tieno[3,2-b]piridina como inibidores de udp glicosiltransferase e métodos de uso - Google Patents

derivados de tieno[3,2-b]piridina como inibidores de udp glicosiltransferase e métodos de uso Download PDF

Info

Publication number
BR112021005914A2
BR112021005914A2 BR112021005914-8A BR112021005914A BR112021005914A2 BR 112021005914 A2 BR112021005914 A2 BR 112021005914A2 BR 112021005914 A BR112021005914 A BR 112021005914A BR 112021005914 A2 BR112021005914 A2 BR 112021005914A2
Authority
BR
Brazil
Prior art keywords
thieno
trifluoromethyl
alkyl
pyridin
methylcarbamoyl
Prior art date
Application number
BR112021005914-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Sungtaek Lim
Sukanthini Thurairatnam
Kwon Yon MUSICK
James Pribish
Michael Angelastro
Robert H. Barker
Mary A. Cromwell
Elina Makino
Bradford Hirth
John Jiang
Sachin Maniar
Mark Munson
Yong-Mi Choi
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of BR112021005914A2 publication Critical patent/BR112021005914A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021005914-8A 2018-10-01 2019-10-01 derivados de tieno[3,2-b]piridina como inibidores de udp glicosiltransferase e métodos de uso BR112021005914A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862739405P 2018-10-01 2018-10-01
US62/739,405 2018-10-01
PCT/US2019/054085 WO2020072504A1 (en) 2018-10-01 2019-10-01 Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
BR112021005914A2 true BR112021005914A2 (pt) 2021-06-29

Family

ID=68296740

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021005914-8A BR112021005914A2 (pt) 2018-10-01 2019-10-01 derivados de tieno[3,2-b]piridina como inibidores de udp glicosiltransferase e métodos de uso

Country Status (15)

Country Link
US (1) US11098056B2 (https=)
EP (1) EP3861000A1 (https=)
JP (1) JP7545979B2 (https=)
KR (1) KR102903997B1 (https=)
CN (1) CN113423711B (https=)
AU (1) AU2019355870B2 (https=)
BR (1) BR112021005914A2 (https=)
CA (1) CA3114722A1 (https=)
CO (1) CO2021005738A2 (https=)
IL (1) IL281811B2 (https=)
MA (1) MA53043B2 (https=)
MX (1) MX2021003794A (https=)
SG (1) SG11202102987VA (https=)
TW (1) TWI821426B (https=)
WO (1) WO2020072504A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4294798A1 (en) * 2021-02-19 2023-12-27 Kalvista Pharmaceuticals Limited Factor xiia inhibitors
EP4483954A1 (en) * 2023-06-29 2025-01-01 Masarykova Univerzita Substituted thieno [3,2-b]pyridines as inhibitors of protein kinases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
BR0012984A (pt) 1999-08-04 2002-07-16 Millennium Pharm Inc Método para tratar um estado associado com o mc4-r em um mamìfero, composto de ligação ao mc4-r, e, composição farmacêutica
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
FR2821356A1 (fr) * 2001-02-23 2002-08-30 Cerep Nouveaux derives d'arylcarbamates et d'arylurees, preparations et utilisations
EP2215094B1 (en) * 2007-11-15 2016-01-27 YM BioSciences Australia Pty Ltd N-containing heterocyclic compounds
US8450363B2 (en) * 2009-02-06 2013-05-28 Elan Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
CN103458970A (zh) * 2011-03-07 2013-12-18 泰莱托恩基金会 Tfeb磷酸化抑制剂及其应用
CA2973949C (en) * 2015-01-16 2023-07-11 The General Hospital Corporation Compounds for improving mrna splicing
SG11201804901WA (en) * 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
KR102530515B1 (ko) * 2016-05-05 2023-05-09 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도
US20190134005A1 (en) 2016-06-10 2019-05-09 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
MX385576B (es) * 2016-11-02 2025-03-18 Janssen Pharmaceutica Nv Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2
WO2018118838A1 (en) * 2016-12-20 2018-06-28 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
BR112019023109A2 (pt) * 2017-05-04 2020-05-26 Glenmark Pharmaceuticals S.A. Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo
EA201992780A1 (ru) * 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания

Also Published As

Publication number Publication date
JP2022508523A (ja) 2022-01-19
AU2019355870A1 (en) 2021-05-20
JP7545979B2 (ja) 2024-09-05
TW202035419A (zh) 2020-10-01
AU2019355870B2 (en) 2023-11-16
SG11202102987VA (en) 2021-04-29
MA53043B2 (fr) 2024-05-31
IL281811A (en) 2021-05-31
MX2021003794A (es) 2021-09-08
WO2020072504A1 (en) 2020-04-09
CN113423711B (zh) 2024-03-15
IL281811B1 (en) 2024-11-01
MA53043A1 (fr) 2022-08-31
CN113423711A (zh) 2021-09-21
IL281811B2 (en) 2025-03-01
US20200102324A1 (en) 2020-04-02
EP3861000A1 (en) 2021-08-11
KR20210087033A (ko) 2021-07-09
KR102903997B1 (ko) 2025-12-26
CO2021005738A2 (es) 2021-05-10
US11098056B2 (en) 2021-08-24
CA3114722A1 (en) 2020-04-09
TWI821426B (zh) 2023-11-11

Similar Documents

Publication Publication Date Title
JP6228199B2 (ja) キナーゼ阻害剤として有用であるイミダゾトリアジンカルボニトリル
KR20220016049A (ko) Btk 억제제 고리 유도체, 이의 제조 방법 및 이의 약제학적 응용
TW201722948A (zh) N-磺醯化吡唑并﹝3,4-b﹞吡啶-6-甲醯胺及其使用方法
JP2025519417A (ja) E3リガーゼリガンドとirak4阻害剤との結合によるirak4の分解及びその使用方法
KR20230028269A (ko) 헌팅턴병을 치료하기 위한 htt 조절제
US11319324B2 (en) Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors
EP3546458B1 (en) ((pyridin-2-yl)-amino)pyrido[3,4-d]pyrimidine and ((pyridazin-3-yl)-amino)pyrido[3,4-d]pyrimidine derivatives as cdk4/6 inhibitors for treating e.g. rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction or cancer
TW202330548A (zh) 用於降解egfr激酶的化合物
WO2020048605A1 (en) Novel pyrrolidine amine compounds for the treatment of autoimmune disease
WO2024192064A1 (en) Compounds and compositions as smarca2/4 degraders and uses thereof
ES3023544T3 (en) Atm kinase inhibitors and compositions and methods of use thereof
CN107428756B (zh) 6-吗啉基-2-吡唑基-9h-嘌呤衍生物及其作为pi3k抑制剂的用途
AU2019355870B2 (en) Thieno[3,2-b]pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use
RU2810928C2 (ru) Ингибиторы уридин-5-дифосфат (udp) гликозилтрансферазы и способы их применения
HK40082036A (en) Atm kinase inhibitors and compositions and methods of use thereof
HK40082036B (en) Atm kinase inhibitors and compositions and methods of use thereof
HK40053673B (zh) 一种btk抑制剂环衍生物及其制备方法和药学上的应用

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]